Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3937423rdf:typepubmed:Citationlld:pubmed
pubmed-article:3937423lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:3937423lifeskim:mentionsumls-concept:C0043117lld:lifeskim
pubmed-article:3937423lifeskim:mentionsumls-concept:C0010961lld:lifeskim
pubmed-article:3937423pubmed:issue2lld:pubmed
pubmed-article:3937423pubmed:dateCreated1986-3-17lld:pubmed
pubmed-article:3937423pubmed:abstractTextFourteen patients with idiopathic thrombocytopenic purpura (ITP) refractory to steroids and/or splenectomy were treated with danazol (200 mg 3 times a day) for 2 months. The following responses were achieved: excellent (platelet count greater than 100 X 10(9)/l) in 5 patients; good (greater than 50 X 10(9)/l, but less than 100 X 10(9)/l) in 2 patients, and poor in (no increase of platelet count) 7 patients. In three cases remission lasted more than 7 months. Danazol was well tolerated and in most patients better suited than steroids for long-term intake.lld:pubmed
pubmed-article:3937423pubmed:languageenglld:pubmed
pubmed-article:3937423pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3937423pubmed:citationSubsetIMlld:pubmed
pubmed-article:3937423pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3937423pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3937423pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3937423pubmed:statusMEDLINElld:pubmed
pubmed-article:3937423pubmed:issn0001-5792lld:pubmed
pubmed-article:3937423pubmed:authorpubmed-author:BarbuiTTlld:pubmed
pubmed-article:3937423pubmed:authorpubmed-author:ComottiBBlld:pubmed
pubmed-article:3937423pubmed:authorpubmed-author:BassanRRlld:pubmed
pubmed-article:3937423pubmed:authorpubmed-author:CortelazzoSSlld:pubmed
pubmed-article:3937423pubmed:authorpubmed-author:VieroPPlld:pubmed
pubmed-article:3937423pubmed:authorpubmed-author:MinettiBBlld:pubmed
pubmed-article:3937423pubmed:authorpubmed-author:BuelliMMlld:pubmed
pubmed-article:3937423pubmed:issnTypePrintlld:pubmed
pubmed-article:3937423pubmed:volume74lld:pubmed
pubmed-article:3937423pubmed:ownerNLMlld:pubmed
pubmed-article:3937423pubmed:authorsCompleteYlld:pubmed
pubmed-article:3937423pubmed:pagination97-8lld:pubmed
pubmed-article:3937423pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:3937423pubmed:meshHeadingpubmed-meshheading:3937423-...lld:pubmed
pubmed-article:3937423pubmed:meshHeadingpubmed-meshheading:3937423-...lld:pubmed
pubmed-article:3937423pubmed:meshHeadingpubmed-meshheading:3937423-...lld:pubmed
pubmed-article:3937423pubmed:meshHeadingpubmed-meshheading:3937423-...lld:pubmed
pubmed-article:3937423pubmed:meshHeadingpubmed-meshheading:3937423-...lld:pubmed
pubmed-article:3937423pubmed:meshHeadingpubmed-meshheading:3937423-...lld:pubmed
pubmed-article:3937423pubmed:meshHeadingpubmed-meshheading:3937423-...lld:pubmed
pubmed-article:3937423pubmed:meshHeadingpubmed-meshheading:3937423-...lld:pubmed
pubmed-article:3937423pubmed:meshHeadingpubmed-meshheading:3937423-...lld:pubmed
pubmed-article:3937423pubmed:meshHeadingpubmed-meshheading:3937423-...lld:pubmed
pubmed-article:3937423pubmed:meshHeadingpubmed-meshheading:3937423-...lld:pubmed
pubmed-article:3937423pubmed:year1985lld:pubmed
pubmed-article:3937423pubmed:articleTitleDanazol for the treatment of idiopathic thrombocytopenic purpura.lld:pubmed
pubmed-article:3937423pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3937423lld:pubmed